文献速递造血干细胞移植与细胞治疗

异基因造血细胞移植后重组带状疱疹疫苗安全性与反应原性

Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation.
PubMed 文献 · Blood Adv · 2021-01-01

这项单中心前瞻性观察队列研究评估了异基因造血细胞移植后接种重组带状疱疹疫苗(RZV)的安全性与反应原性。征集性反应发生率92.1%(3级32.5%),移植后疫苗期GVHD累积发生率与历史对照无差异(调整发病率比1.05,95%CI 0.8-1.38)。结论认为RZV安全、可耐受且不增加GVHD。

要点

  • 异基因HCT后9-24个月接种2剂RZV,征集性反应常见但多为轻度。
  • 疫苗期GVHD累积发生率与历史对照无显著差异。
  • 总接种队列带状疱疹发生率2.5%,需进一步研究免疫原性与效力。

核心结论

  • 异基因HCT受者接种RZV安全、可耐受,且不增加GVHD发生率。

主要发现

  • 征集性反应发生于92.1%的患者,3级反应占32.5%,主要为注射部位疼痛(86%,3级16%)。
  • 疫苗期GVHD累积发生率与历史对照无差异(调整发病率比1.05,95%CI 0.8-1.38)。
  • 总接种队列带状疱疹4例(2.5%),完成2剂队列3例(28.3/1000人年)。

临床怎么用

  • 异基因HCT后9-24个月可考虑接种2剂RZV,需告知患者常见注射部位疼痛等反应。
  • 接种期间无需因GVHD风险而禁忌接种,但应继续监测GVHD。

局限性

  • 单中心观察性研究,缺乏同期对照组,GVHD比较采用历史对照。
  • 未评估免疫原性与疫苗效力,需未来临床试验确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (HCT) recipients are at increased risk for varicella zoster virus (VZV) reactivation and associated complications. A nonlive adjuvanted recombinant zoster vaccine (RZV) has been developed to prevent herpes zoster (HZ), but there are no recommendations for use in this population. In this single-center prospective observational cohort study, we assessed the safety and reactogenicity of RZV, as well as incidence of graft-versus-host disease (GVHD) and confirmed cases of HZ after vaccination. Between December of 2018 and June of 2020, patients aged ≥18 years received 2 doses of RZV between 9 and 24 months after HCT, with the doses separated by ≥8 weeks. One hundred and fifty-eight patients (mean age, 55 years; 42% women) received ≥1 dose (total vaccinated cohort), and 150 patients (95%) received 2 doses (modified total vaccinated cohort). Solicited reactions occurred in 92.1% of patients (grade 3, 32.5%), owing mostly to injection site pain, which occurred in 86% (grade 3, 16%). The cumulative incidence of GVHD in the peri-vaccination period was no different than in historical controls (adjusted incidence rate ratio, 1.05; 95% confidence interval, 0.8-1.38). There were 4 cases of HZ in the total vaccinated cohort (2.5%) and 3 cases in the modified total vaccinated cohort (28.3/1000 person-years). Among recipients of allogeneic HCT, RZV was safe, tolerable, and did not increase rates of GVHD. Future clinical trials are needed to determine the immunogenicity and efficacy of RZV in this population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Baumrin E, Izaguirre NE, Bausk B, et al. Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation. Blood Adv. 2021. PMID: 33710336. doi:10.1182/bloodadvances.2020003749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。